Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in the Department of General Surgery at Cleveland Clinic’s main campus.. In this video, he speaks about the article Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases.
Question on Key Points
What are the estimated overall and recurrence-free survival outcomes following living-donor liver transplantation (LDLT) in patients with liver-confined, unresectable colorectal cancer liver metastases (CRLM)?
Conclusions:
At a median follow-up of 1.5 years, Kaplan-Meier estimates of recurrence-free and overall survival in this cohort analysis of 10 persons with CRLM who had LDLT were 62 percent and 100 percent, respectively. Perioperative outcomes were consistent with recognized benchmarks for both recipients and donors.
Indicating: The findings show that LDLT may be a viable therapy option for patients with unresectable CRLMs who have good tumor biology.